Pan-BCL2 family inhibitor obatoclax as treatment for parental and cisplatin-resistant triple negative breast cancer
Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Nowadays, only chemotherapy and radi otherapy are standard treatments for TNBC. Cancer stem cells population (CSCs) are one of the most important mechanism to appear chemoresistance process. B...
| Autores: | , , , , , , |
|---|---|
| Tipo de recurso: | capítulo de libro |
| Fecha de publicación: | 2020 |
| País: | España |
| Institución: | Universidad de Castilla-La Mancha |
| Repositorio: | RUIdeRA. Repositorio Institucional de la UCLM |
| OAI Identifier: | oai:ruidera.uclm.es:10578/30500 |
| Acceso en línea: | http://hdl.handle.net/10578/30500 |
| Access Level: | acceso abierto |
| Palabra clave: | Triple negative breast cancer Obatoclax Cisplatin Resistant BCL2 family |
| Sumario: | Triple negative breast cancer (TNBC) is an incurable disease where novel therapeutic strategies are needed. Nowadays, only chemotherapy and radi otherapy are standard treatments for TNBC. Cancer stem cells population (CSCs) are one of the most important mechanism to appear chemoresistance process. BCL2 family proteins are involved in apoptosis. We hypothesized that they be engaged in acquisition of resistance mechanism to chemotherapy due to the alteration of this family in CSCs population. So, in this work, we explored the antitumoral activity of BCL2 family proteins inhibitors, specifi cally, obatoclax (a pan-BCL2 family proteins inhibitor) in TNBC cells and in a chemoresistant TNBC cell model. |
|---|